Allergan Pulls EU Filing For Abicipar Pegol

Move Follows Rejection Of US Application

 
• By Maureen Kenny

The withdrawal of the EU filing for abicipar pegol will fuel speculation that Allergan parent AbbVie is indeed ditching the potential treatment for wet AMD. US regulators have already said they won't approve the drug.

Macular_Degeneration
AMD affects the middle part of one's vision • Source: Shutterstock

More from Product Reviews

More from Pink Sheet